BR112021016974A2 - Compostos de pirazolopiridina para inibição de ire1 - Google Patents
Compostos de pirazolopiridina para inibição de ire1Info
- Publication number
- BR112021016974A2 BR112021016974A2 BR112021016974A BR112021016974A BR112021016974A2 BR 112021016974 A2 BR112021016974 A2 BR 112021016974A2 BR 112021016974 A BR112021016974 A BR 112021016974A BR 112021016974 A BR112021016974 A BR 112021016974A BR 112021016974 A2 BR112021016974 A2 BR 112021016974A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- pyrazolopyridine compounds
- ire1
- inhibition
- disorder
- Prior art date
Links
- 150000005229 pyrazolopyridines Chemical class 0.000 title abstract 3
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
compostos de pirazolopiridina para inibição de ire1. a presente invenção fornece novos compostos de pirazolopiridina, composições e métodos para tratamento ou prevenção de uma doença ou distúrbio relacionado com ire1a. em certas modalidades, a doença ou distúrbio é selecionada do grupo que consiste em uma doença neurodegenerativa, uma doença desmielinizante, câncer, uma doença ocular, uma doença fibrótica e diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811237P | 2019-02-27 | 2019-02-27 | |
| US201962813975P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/020162 WO2020176765A1 (en) | 2019-02-27 | 2020-02-27 | Pyrazolopyridine compounds for ire1 inhibition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016974A2 true BR112021016974A2 (pt) | 2021-11-30 |
Family
ID=72238956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016974A BR112021016974A2 (pt) | 2019-02-27 | 2020-02-27 | Compostos de pirazolopiridina para inibição de ire1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220153734A1 (pt) |
| EP (1) | EP3930718A4 (pt) |
| JP (1) | JP2022521784A (pt) |
| KR (1) | KR20210139280A (pt) |
| CN (1) | CN113795254B (pt) |
| AU (1) | AU2020228644A1 (pt) |
| BR (1) | BR112021016974A2 (pt) |
| CA (1) | CA3131388A1 (pt) |
| IL (1) | IL285794A (pt) |
| MX (1) | MX2021010345A (pt) |
| SG (1) | SG11202109194UA (pt) |
| WO (1) | WO2020176765A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4192462A4 (en) * | 2020-08-07 | 2024-09-04 | Optikira Llc | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US8980899B2 (en) * | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| CN104995192A (zh) * | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
| WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| WO2017152126A1 (en) * | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| WO2018161033A1 (en) * | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| CA3064837A1 (en) * | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| AU2018326721B2 (en) * | 2017-09-01 | 2022-12-01 | Optikira, LLC | Compounds and compositions for IRE1 inhibition |
| EP4192462A4 (en) * | 2020-08-07 | 2024-09-04 | Optikira Llc | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM |
-
2020
- 2020-02-27 CA CA3131388A patent/CA3131388A1/en active Pending
- 2020-02-27 US US17/432,842 patent/US20220153734A1/en active Pending
- 2020-02-27 EP EP20762408.1A patent/EP3930718A4/en active Pending
- 2020-02-27 WO PCT/US2020/020162 patent/WO2020176765A1/en unknown
- 2020-02-27 AU AU2020228644A patent/AU2020228644A1/en active Pending
- 2020-02-27 BR BR112021016974A patent/BR112021016974A2/pt unknown
- 2020-02-27 KR KR1020217030762A patent/KR20210139280A/ko unknown
- 2020-02-27 JP JP2021549956A patent/JP2022521784A/ja active Pending
- 2020-02-27 MX MX2021010345A patent/MX2021010345A/es unknown
- 2020-02-27 CN CN202080031022.8A patent/CN113795254B/zh active Active
- 2020-02-27 SG SG11202109194UA patent/SG11202109194UA/en unknown
-
2021
- 2021-08-23 IL IL285794A patent/IL285794A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113795254B (zh) | 2024-08-09 |
| MX2021010345A (es) | 2021-12-15 |
| EP3930718A1 (en) | 2022-01-05 |
| JP2022521784A (ja) | 2022-04-12 |
| US20220153734A1 (en) | 2022-05-19 |
| AU2020228644A1 (en) | 2021-09-23 |
| CN113795254A (zh) | 2021-12-14 |
| CA3131388A1 (en) | 2020-09-03 |
| KR20210139280A (ko) | 2021-11-22 |
| EP3930718A4 (en) | 2022-10-05 |
| IL285794A (en) | 2021-10-31 |
| WO2020176765A1 (en) | 2020-09-03 |
| SG11202109194UA (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| MX2020002322A (es) | Compuestos y composiciones para la inhibicion de ire1. | |
| BR112018008918A8 (pt) | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
| BR112016014952A2 (pt) | Inibição direcionada de tgfbeta | |
| BR112021020441A2 (pt) | Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra | |
| CR20210393A (es) | COMPOSICIONES DE AGENTE DE ARNi DE PROTEÍNA PRECURSORA DE AMILOIDE (APP) Y MÉTODO DE USO DE LAS MISMAS | |
| BR112017003571A2 (pt) | terapia combinada | |
| BR112018069147A2 (pt) | composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh | |
| PH12021550558A1 (en) | Modulators of pnpla3 expression | |
| BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
| BR112022012280A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| CR20200631A (es) | Modulares de la expresión de apol1 | |
| MX2021007503A (es) | Moduladores de la expresion de hsd17b13. | |
| MX2019003569A (es) | Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos. | |
| BR112017009010A2 (pt) | moduladores potentes de gama-secretase | |
| BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 |